Les médicaments hypoglycémiants du diabète de type 2 ont-ils des effets collatéraux cardiovasculaires ? État des lieux en mars 2015
(2015) 12e Congrès UCL d’Endocrino-Diabétologie — Location: (Belgium) Bruxelles (21.March.2015)
Files
2015_Buysschaert_LM_1343_97-101.pdf
Restricted Access - Adobe PDF
- 127.58 KB
Details
- Authors
- Abstract
- (en) [Do hypoglycemic treatments show collateral cardiovascular effects? The state of the art as of March 2015?] Given the clinical context of Type 2 diabetes with increased risk of cardiovascular complications, it is essential to evaluate the potential associated cardiovascular side-effects (be they positive or negative) of antihyperglycemic treatments. New therapeutic agents for Type 2 diabetes should at least demonstrate cardiovascular neutrality (meaning non-inferiority) versus comparators, or even better, added value. This paper sought to review the cardiovascular effects of treatments currently administered to Type 2 diabetic patients, including metformin, sulfonylureas, glitazones, incretinomimetics (GLP-1 agonists and DPP-4 inhibitors), as well as gliflozins. To date, most studies seem to suggest that these drugs are associated with cardiovascular safety, despite contradictory data as regards several therapeutic agents. Long-term, well-designed cardiovascular studies should be performed to confirm the current assumptions about cardiovascular safety of these drugs.
- Affiliations
Citations
Buysschaert, M., & Medina, J. L. (2015). Les médicaments hypoglycémiants du diabète de type 2 ont-ils des effets collatéraux cardiovasculaires ? État des lieux en mars 2015. Louvain médical, 134(3), 97-101. https://hdl.handle.net/2078.5/82791 (Original work published 2015)